Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News HCW Biologics Inc HCWB

Healthcare Biotechnology
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID... see more

Recent & Breaking News (NDAQ:HCWB)

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

GlobeNewswire 1 day ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

GlobeNewswire November 18, 2024

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

GlobeNewswire November 18, 2024

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 14, 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

GlobeNewswire August 23, 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 14, 2024

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire May 15, 2024

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

GlobeNewswire April 1, 2024

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

GlobeNewswire November 14, 2023

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

GlobeNewswire November 8, 2023

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

GlobeNewswire November 1, 2023

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 - 13, 2023

GlobeNewswire September 6, 2023

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire August 11, 2023

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

GlobeNewswire June 14, 2023

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

GlobeNewswire May 9, 2023

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

GlobeNewswire April 27, 2023

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

GlobeNewswire April 13, 2023

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

GlobeNewswire April 3, 2023

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

GlobeNewswire March 28, 2023

HCW Biologics Enters CRADA with National Cancer Institute

GlobeNewswire December 8, 2022